240
Participants
Start Date
September 14, 2024
Primary Completion Date
January 16, 2025
Study Completion Date
March 6, 2025
3mg TQC3721 Suspension for Inhalation
TQC3721 suspension for inhalation is target inhibitor.
6mg TQC3721 Suspension for Inhalation
TQC3721 suspension for inhalation is target inhibitor.
Placebo TQC3721 suspension for inhalation
Placebo without active drug substance.
Shanghai JiaoTong University of medicine Ruijin Hospital, Shanghai
Cangzhou Hospital of Integrated Tcm-Wm·Hebei, Cangzhou
Genertec Liaoyou Gem Flower Hospital, Panjin
The First Hospital of Jilin University, Changchun
Siping Central People's Hospital, Siping
Wuxi Fifth People's Hospital, Wuxi
Yixing People'S Hospital, Wuxi
Northern Jiangsu People's Hospital, Yangzhou
Fu Yang People'S Hospital, Fuyang
Heze Municipal Hospital, Heze
Tianjin Medical University General Hospital, Tianjin
TianJin 4th Center Hospital, Tianjin
Wenzhou University Affiliated Second Hospital, Wenzhou
Jiangxi Provincial People's Hospital, Nanchang
The Second Affiliated Hospital of Xiamen Medical College, Xiamen
ChongQing University Fuling Hospital, Chongqing
Puyang Oilfield General Hospital, Puyang
Shangqiu First People's Hospita, Shangqiu
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
Zunyi Medical University Affiliated Hospital, Zunyi
West China Hospital of Sichuan University, Chengdu
Suining Central Hospital, Suining
The First Hospital of Lanzhou University, Lanzhou
The First Affiliated Hospital of Shihezi University, Shihezi
The Third Hospital of Hebei Medical University, Shijiazhuang
Chifeng Municipal Hospital, Chifeng
Shanxi Bethune Hospital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY